SCPH

scPharmaceuticals Inc. [SCPH] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SCPH Stock Summary

Top 10 Correlated ETFs

SCPH


Top 10 Correlated Stocks

SCPH


In the News

07:32 29 Mar 2024 SCPH

scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript

scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript

04:01 29 Mar 2024 SCPH

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m.

04:01 29 Mar 2024 SCPH

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences.

02:57 29 Mar 2024 SCPH

scPharmaceuticals Q3 Earnings: Cruising Toward Success

Q3 earnings report shows positive performance, with Furoscix net sales exceeding consensus estimates. scPharmaceuticals' progress in securing payer coverage and IDN agreements is driving confidence in its prospects. The company's healthy financial position and potential market opportunity for Furoscix make it an undervalued investment.

11:03 29 Mar 2024 SCPH

Short squeeze alert for November 9th: 2 stocks that could surge

Among various strategies and methods used in stock trading, shorting is a daring one. Seen as a high-risk approach, it involves borrowing and selling stocks, betting on their price decline.

09:58 29 Mar 2024 SCPH

scPharmaceuticals Inc (SCPH) Q3 2023 Earnings Call Transcript

scPharmaceuticals Inc (NASDAQ:SCPH ) Q3 2023 Earnings Call Transcript November 8, 2023 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Nik Gasic - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Capital Group Operator Thank you for standing by.

08:00 29 Mar 2024 SCPH

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences.

12:40 29 Mar 2024 SCPH

scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD

Positive FDA feedback for Furoscix's label expansion into chronic kidney disease signals the potential for significant market growth. Introduction of a higher concentration auto-injector formulation of Furoscix could reduce costs and enhance patient convenience. Q2 earnings show encouraging market momentum for Furoscix, with continued demand and growth in prescribers.

02:13 29 Mar 2024 SCPH

Sizing Up scPharmaceuticals

Today, we take our first look at scPharmaceuticals Inc., which has received positive analyst commentary but has a large short position in the stock. The company just launched its franchise product FUROSCIX in February of this year and management believes it has huge potential. Analysts expect sales to reach nearly $40 million in FY2024, but the company is projected to continue experiencing losses.

08:00 29 Mar 2024 SCPH

scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BURLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13 at 10:00 am ET. In addition to the fireside chat, Mr. Tucker will also be meeting with investors.

SCPH Financial details

Company Rating
Neutral
Market Cap
186.4M
Income
-56.43M
Revenue
13.59M
Book val./share
0.96
Cash/share
1.96
Dividend
-
Dividend %
-
Employees
135
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-4.65
Forward P/E
-8.51
PEG
-4.09
P/S
30.04
P/B
4.95
P/C
2.56
P/FCF
-4.03
Quick Ratio
8.62
Current Ratio
9.53
Debt / Equity
1.05
LT Debt / Equity
1.04
-
-
EPS (TTM)
-1.47
EPS next Y
-0.59
EPS next Q
-0.42
EPS this Y
7.58%
EPS next Y
-60.2%
EPS next 5Y
-350.79%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
60.59%
EPS Q/Q
-10%
-
-
-
-
SMA20
-11.56%
SMA50
-14.47%
SMA100
-3.7%
Inst Own
69.2%
Inst Trans
0.92%
ROA
-49%
ROE
31%
ROC
-0.52%
Gross Margin
73%
Oper. Margin
-662%
Profit Margin
-699%
Payout
-
Shs Outstand
36.05M
Shs Float
23.45M
-
-
-
-
Target Price
-
52W Range
4.63-12.75
52W High
-58.17%
52W Low
+25.5%
RSI
41.01
Rel Volume
0.47
Avg Volume
231.8K
Volume
110.06K
Perf Week
-6.52%
Perf Month
-10.99%
Perf Quarter
-24.28%
Perf Half Y
-29.49%
-
-
-
-
Beta
0.073
-
-
Volatility
0.24%, 0.36%
Prev Close
-0.2%
Price
5.02
Change
-0.59%

SCPH Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000.35
Net income per share
-1.85-1.4-1.11-1.32-1.42
Operating cash flow per share
-1.64-1.13-0.99-1.22-1.54
Free cash flow per share
-1.64-1.13-0.99-1.22-1.54
Cash per share
3.915.642.754.171.97
Book value per share
-6.96-6.58-6.94-7.990.97
Tangible book value per share
2.763.342.062.550.97
Share holders equity per share
-6.96-6.58-6.94-7.990.97
Interest debt per share
1.180.930.741.431.22
Market cap
105.28M129.97M137.31M203.33M241.48M
Enterprise value
52.74M44.9M80.67M169.64M234.94M
P/E ratio
-3.06-3.78-4.5-5.42-4.41
Price to sales ratio
000017.77
POCF ratio
-3.46-4.69-5.06-5.88-4.08
PFCF ratio
-3.46-4.69-5.06-5.88-4.07
P/B Ratio
-0.81-0.8-0.72-0.96.49
PTB ratio
-0.81-0.8-0.72-0.96.49
EV to sales
000017.28
Enterprise value over EBITDA
-1.69-1.52-3.17-5.06-4.29
EV to operating cash flow
-1.73-1.62-2.97-4.91-3.97
EV to free cash flow
-1.73-1.62-2.97-4.9-3.96
Earnings yield
-0.33-0.26-0.22-0.18-0.23
Free cash flow yield
-0.29-0.21-0.2-0.17-0.25
Debt to equity
-0.16-0.12-0.09-0.161.05
Debt to assets
0.260.190.220.30.41
Net debt to EBITDA
1.682.872.2210.12
Current ratio
14.4411.575.2716.637.08
Interest coverage
-18.62-11.57-10.03-10.95-6.82
Income quality
0.920.860.970.941.08
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00003.93
Research and developement to revenue
00000.87
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00-0.02-0.04-0.06
Stock based compensation to revenue
00000.36
Graham number
17.0214.413.1915.425.56
ROIC
0.320.230.160.2-0.71
Return on tangible assets
-0.45-0.32-0.39-0.3-0.58
Graham Net
2.64.551.932.420.69
Working capital
70.41M98.51M63.43M115.89M79.8M
Tangible asset value
51.37M82.17M56.47M72.43M37.22M
Net current asset value
49.73M80.95M55.71M71.55M35.68M
Invested capital
-0.16-0.12-0.09-0.161.05
Average receivables
394.5K155K01.14M3.39M
Average payables
864.5K1.4M1.11M1.03M2.76M
Average inventory
2.01M1.22M0615K5.04M
Days sales outstanding
0000120.54
Days payables outstanding
1.15K1.52K453.331.18K383.2
Days of inventory on hand
2.44K00959.29846.65
Receivables turnover
00003.03
Payables turnover
0.320.240.810.310.95
Inventory turnover
0.15000.380.43
ROE
0.270.210.160.17-1.47
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.050.040.10.16
Net income per share
-0.31-0.34-0.37-0.4-0.36
Operating cash flow per share
-0.38-0.44-0.37-0.35-0.39
Free cash flow per share
-0.38-0.44-0.37-0.35-0.39
Cash per share
3.783.072.662.331.96
Book value per share
-7.25-6.29-6.511.270.96
Tangible book value per share
2.322.011.641.270.96
Share holders equity per share
-7.25-6.29-6.511.270.96
Interest debt per share
1.261.051.030.971.06
Market cap
224.09M342.85M394.28M275.98M243.19M
Enterprise value
190.4M305.08M360.94M280.75M236.65M
P/E ratio
-5.74-6.68-6.96-4.41-4.4
Price to sales ratio
0166.19240.7172.739.89
POCF ratio
-18.93-20.79-27.88-20.52-16.04
PFCF ratio
-18.92-20.79-27.88-20.52-16
P/B Ratio
-0.99-1.44-1.575.626.53
PTB ratio
-0.99-1.44-1.575.626.53
EV to sales
0147.88220.3573.9638.82
Enterprise value over EBITDA
-26.12-32.98-29.72-18.92-15.65
EV to operating cash flow
-16.08-18.5-25.52-20.87-15.61
EV to free cash flow
-16.08-18.5-25.52-20.87-15.57
Earnings yield
-0.04-0.04-0.04-0.06-0.06
Free cash flow yield
-0.05-0.05-0.04-0.05-0.06
Debt to equity
-0.16-0.16-0.150.811.05
Debt to assets
0.30.30.330.380.41
Net debt to EBITDA
4.624.082.75-0.320.43
Current ratio
16.6316.3817.129.537.08
Interest coverage
-4.85-5.89-6.847.2-7.29
Income quality
1.281.4710.861.1
Dividend Yield
00000
Payout ratio
-0.010000
Sales general and administrative to revenue
05.287.3800
Research and developement to revenue
01.031.790.90.55
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
0000-0.01
Capex to depreciation
-0.050-0.030-0.26
Stock based compensation to revenue
00.480.720.340.23
Graham number
7.146.937.323.392.77
ROIC
0.050.070.07-0.16-0.2
Return on tangible assets
-0.08-0.1-0.12-0.15-0.15
Graham Net
2.21.811.451.030.68
Working capital
115.89M118.93M106.94M93.39M79.8M
Tangible asset value
72.43M75.81M63.43M49.15M37.22M
Net current asset value
71.55M75.1M62.83M47.38M35.68M
Invested capital
-0.16-0.16-0.150.811.05
Average receivables
1.14M2.64M2.31M2.89M4.33M
Average payables
1.26M1.57M1.4M2.28M3.69M
Average inventory
615K2.43M4.73M6.48M7.98M
Days sales outstanding
0131.0588.4698.9966.27
Days payables outstanding
1.14K241.88300.51281.09203.1
Days of inventory on hand
922.5538.661.48K594.13448.73
Receivables turnover
00.691.020.911.36
Payables turnover
0.080.370.30.320.44
Inventory turnover
0.10.170.060.150.2
ROE
0.040.050.06-0.32-0.37
Capex per share
00000

SCPH Frequently Asked Questions

What is scPharmaceuticals Inc. stock symbol ?

scPharmaceuticals Inc. is a US stock , located in Burlington of Ma and trading under the symbol SCPH

What is scPharmaceuticals Inc. stock quote today ?

scPharmaceuticals Inc. stock price is $5.02 today.

Is scPharmaceuticals Inc. stock public?

Yes, scPharmaceuticals Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap